FBN1 Antibody

What is FBN1 and why is it significant in research?

FBN1 (Fibrillin-1) is a large extracellular matrix glycoprotein (approximately 350 kDa) that forms thread-like microfibril filaments. These microfibrils serve multiple critical functions: providing structural support for tissues, forming elastic fibers in skin and blood vessels, regulating transforming growth factor beta (TGF-β) availability, and modulating the cellular microenvironment . FBN1 is particularly significant in research because it is the causative gene for Marfan syndrome, an inherited connective tissue disorder characterized by tall stature, arachnodactyly, ectopia lentis, and thoracic aortic aneurysm and dissection . Additionally, mutations in specific regions of FBN1 can result in opposite phenotypes, such as the short stature and brachydactyly seen in Weill-Marchesani syndrome and other acromelic dysplasias . Recent research has also identified FBN1 as a key gene associated with prognosis in squamous cell carcinoma , expanding its relevance to cancer research.

What types of FBN1 antibodies are commercially available for research applications?

There are several types of FBN1 antibodies available for research, with polyclonal rabbit antibodies being commonly used. These antibodies typically target specific epitopes within the fibrillin-1 protein. Examples include:

• Polyclonal antibodies like ab231094 (suitable for Western blot and immunohistochemistry with paraffin-embedded tissues)

• Polyclonal antibodies such as 29425-1-AP (applicable for Western blot, immunohistochemistry, immunofluorescence/immunocytochemistry, co-immunoprecipitation, and ELISA)

These antibodies vary in their reactivity with species (human, rat) and in their validated applications, making selection dependent on the specific experimental design and target species .

What are the expected molecular weights for FBN1 detection in Western blot applications?

The expected molecular weights for FBN1 detection in Western blot applications can vary based on the specific antibody used and the sample type. Researchers should be aware of the following patterns:

The variation between predicted and observed molecular weights may result from post-translational modifications, proteolytic processing, alternative splicing, or degradation during sample preparation. When establishing a new protocol, researchers should validate their specific antibody against appropriate positive controls .

How should researchers optimize antibody dilutions for different FBN1 detection methods?

Optimization of antibody dilutions is critical for achieving specific signal with minimal background. Based on the literature, researchers should consider the following starting dilutions for FBN1 antibodies:

When optimizing dilutions, researchers should:

• Perform a dilution series experiment with positive and negative controls

• Evaluate signal-to-noise ratio at different dilutions

• Consider sample type specificity (human vs. rat)

• Titrate the antibody for each specific experimental system

For challenging samples or applications with high background, additional blocking optimization may be necessary.

What are the critical considerations when validating FBN1 antibody specificity?

Validating FBN1 antibody specificity is essential given the large size of the protein and the potential for cross-reactivity. Key validation approaches include:

• Multiple detection methods comparison: Compare results from Western blot, immunohistochemistry, and immunofluorescence to ensure consistent detection patterns.

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide/protein (e.g., Fibrillin-1 fusion protein Ag30283 for 29425-1-AP) to confirm signal reduction or elimination .

• Genetic models: When available, use samples from FBN1 knockout/knockdown systems as negative controls or samples from mouse models with specific FBN1 mutations.

• Band pattern analysis: For Western blot applications, compare observed band patterns with predicted molecular weights. FBN1 detection should align with expected sizes (312-350 kDa), though processing variants at 25 kDa and 43 kDa have been documented in human lung lysate .

• Cross-species validation: If the antibody is predicted to work across species, confirm reactivity by testing samples from multiple species and comparing signal patterns.

• Literature concordance: Verify that your findings align with published literature regarding localization patterns and expression levels in various tissues.

How can researchers troubleshoot inconsistent banding patterns when using FBN1 antibodies?

Inconsistent banding patterns are a common challenge when working with large proteins like FBN1. Troubleshooting approaches include:

• Sample preparation optimization:

  • Use protease inhibitors to prevent degradation

  • Adjust lysis buffer composition to better solubilize the protein

  • Consider gentler homogenization techniques for tissue samples

  • Test different protein extraction protocols specific to extracellular matrix proteins

• Gel electrophoresis conditions:

  • Use gradient gels (3-8% or 4-12%) for better resolution of high molecular weight proteins

  • Extend running time to achieve better separation

  • Consider specialized systems designed for large proteins

• Transfer conditions:

  • Use wet transfer rather than semi-dry for large proteins

  • Increase transfer time and/or reduce voltage

  • Add SDS to transfer buffer (0.05-0.1%) to aid transfer of large proteins

  • Consider specialized transfer systems for high molecular weight proteins

• Antibody incubation:

  • Test different blocking agents (BSA vs. milk)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Optimize antibody dilution in a systematic manner

• Positive controls:

  • Include recombinant FBN1 protein as a positive control

  • Use well-characterized tissue lysates known to express FBN1 (e.g., lung tissue)

How can FBN1 antibodies be used to study Marfan syndrome and related disorders?

FBN1 antibodies are valuable tools for studying Marfan syndrome and related disorders through multiple approaches:

• Tissue distribution analysis: Researchers can use immunohistochemistry or immunofluorescence to examine the distribution and organization of fibrillin-1 in tissues affected by Marfan syndrome, such as aorta, skin, and ocular tissues. Abnormal microfibril formation can be visualized and quantified .

• Mutation effect studies: For the over 1,000 known mutations in FBN1 associated with Marfan syndrome, antibodies can help determine how specific mutations affect protein expression, stability, and incorporation into microfibrils. This is particularly relevant for missense mutations, which represent approximately two-thirds of all reported FBN1 mutations .

• Domain-specific investigations: Using FBN1 antibodies targeting specific domains can help elucidate how mutations in different regions lead to distinct phenotypes. For example, researchers can investigate how mutations in the "neonatal" region (TB5 and cbEGF18 domains) result in severe neonatal Marfan syndrome, or how mutations in the 4th 8-cysteine domain containing the RGD sequence lead to stiff skin syndrome .

• TGF-β signaling studies: Since fibrillin-1 regulates TGF-β availability, FBN1 antibodies can be used in combination with TGF-β pathway markers to investigate how mutations affect this critical signaling pathway, which is thought to contribute significantly to the pathogenesis of Marfan syndrome .

• Therapeutic evaluation: In preclinical studies of potential therapies, FBN1 antibodies can help assess whether interventions successfully restore normal fibrillin-1 deposition and microfibril formation.

What methodological approaches should be used when studying FBN1 mutations with antibodies?

When studying FBN1 mutations using antibodies, researchers should consider the following methodological approaches:

• Mutation-specific considerations:

  • For missense mutations affecting cysteine residues (common in cbEGF domains), examine protein misfolding and retention using cellular localization studies

  • For splice site mutations resulting in exon skipping, use antibodies that can detect truncated forms of fibrillin-1

  • For large deletions/insertions, confirm the specificity of your antibody relative to the mutation site

• Multi-method validation:

  • Combine Western blot with immunohistochemistry or immunofluorescence

  • Use co-immunoprecipitation to assess interactions with other extracellular matrix components

  • Consider pulse-chase experiments to evaluate protein stability and secretion rates

• Controls and comparisons:

  • Include samples from multiple patients with the same mutation when possible

  • Use appropriate family member controls (affected vs. unaffected)

  • Consider using engineered cell lines with specific FBN1 mutations as controlled model systems

• Specialized techniques:

  • Use immunoelectron microscopy to visualize microfibril assembly defects

  • Apply immunoprecipitation followed by mass spectrometry to identify altered protein interactions

  • Consider proximity ligation assays to study in situ protein interactions

• Model system selection:

  • Different mouse models exist for various FBN1 mutations (C1039G, GT-8, H1Δ, WMΔ), offering specific advantages for different research questions

  • Patient-derived fibroblasts or induced pluripotent stem cells can provide human-relevant disease models

How do sample preparation methods affect FBN1 detection in different experimental systems?

Sample preparation significantly impacts FBN1 detection due to its large size, extensive post-translational modifications, and extracellular matrix localization:

• Tissue preparation for immunohistochemistry:

  • For paraffin-embedded tissues, antigen retrieval is critical; TE buffer pH 9.0 is recommended for optimal results with some antibodies, though citrate buffer pH 6.0 may be used as an alternative

  • Fixation time should be optimized, as excessive fixation can mask epitopes

  • Section thickness (4-6 μm) is important for adequate penetration of antibodies

• Protein extraction for Western blot:

  • Standard RIPA buffer may be insufficient for full extraction of fibrillin-1 from the extracellular matrix

  • Consider specialized extraction buffers containing higher detergent concentrations or chaotropic agents

  • Mechanical disruption methods should be optimized to ensure complete homogenization without protein degradation

  • Include a complete protease inhibitor cocktail to prevent degradation

• Cell culture considerations:

  • Allow sufficient time for fibrillin-1 secretion and microfibril assembly (typically 48-72 hours post-confluence)

  • Collect both cell lysate and conditioned media, as fibrillin-1 is secreted

  • Consider using matrix deposition assays to evaluate fibrillin-1 incorporation into the extracellular matrix

• Storage conditions:

  • FBN1 antibodies are typically stable for one year when stored at -20°C

  • For long-term storage, aliquoting is recommended to avoid freeze-thaw cycles

  • Some antibody preparations include 0.1% BSA for stability

What is the role of FBN1 antibodies in cancer research?

FBN1 antibodies are increasingly valuable in cancer research due to emerging evidence of FBN1's role in tumor biology:

• Prognostic biomarker studies: Recent comprehensive analysis of multi-omics data has identified FBN1 as a key gene associated with the prognosis of squamous cell carcinoma . FBN1 antibodies can be used to assess expression levels in patient samples and correlate with clinical outcomes.

• Tumor microenvironment investigation: Fibrillin-1 contributes to the extracellular matrix composition, which is known to influence tumor progression and metastasis. FBN1 antibodies allow researchers to:

  • Evaluate matrix remodeling during tumor progression

  • Examine the spatial relationship between fibrillin-1 deposition and infiltrating immune cells

  • Study how fibrillin-1 alterations affect tumor cell invasion and migration

• TGF-β signaling modulation: Since fibrillin-1 regulates TGF-β bioavailability, antibodies can help investigate how altered FBN1 expression affects this pathway in cancer, particularly important since TGF-β signaling can be both tumor-suppressive and tumor-promoting depending on context.

• Validation in diverse cancer types: FBN1 antibodies have been used to detect expression in various cancer tissues, including endometrial cancer, according to validated immunohistochemistry protocols .

How can researchers effectively use FBN1 antibodies in co-labeling experiments?

Co-labeling experiments with FBN1 antibodies require careful planning and optimization:

• Antibody compatibility consideration:

  • When using multiple primary antibodies, select those raised in different host species to avoid cross-reactivity

  • If using multiple rabbit antibodies, consider sequential immunostaining with complete blocking steps between antibodies

  • Validate each antibody individually before attempting co-labeling

• Recommended co-labeling partners:

  • Elastin antibodies to study elastic fiber formation

  • TGF-β and related signaling molecules to investigate regulatory interactions

  • Integrin antibodies, particularly those recognizing RGD-binding integrins, to study cell-matrix interactions

  • Other extracellular matrix components that interact with fibrillin-1 (e.g., fibronectin, collagens)

• Optimization strategies:

  • Adjust antibody concentrations individually for co-labeling experiments

  • Test different fixation and permeabilization protocols to ensure optimal detection of all targets

  • Consider signal amplification methods for targets with low expression

  • Use appropriate controls to confirm specificity, including single-labeled samples

• Advanced imaging considerations:

  • For confocal microscopy, carefully select fluorophores with minimal spectral overlap

  • Consider spectral unmixing for overlapping fluorophores

  • Use appropriate negative controls to set threshold levels for co-localization analysis

  • Employ super-resolution microscopy techniques for detailed analysis of fibrillin-1 microfibril structure

What emerging technologies might enhance FBN1 antibody applications in research?

Several emerging technologies hold promise for enhancing FBN1 antibody applications:

• Single-cell protein analysis: Adapting FBN1 antibodies for use in mass cytometry or microfluidic-based single-cell protein analysis could reveal cell-specific expression patterns and heterogeneity.

• In vivo imaging: Development of non-invasive imaging methods using labeled FBN1 antibodies or fragments could allow longitudinal studies of fibrillin-1 deposition in animal models.

• Proximity labeling techniques: BioID or APEX2-based proximity labeling combined with FBN1 antibodies for purification could identify novel interaction partners in different physiological and pathological contexts.

• Engineered antibody derivatives: Single-chain variable fragments (scFvs) or nanobodies against FBN1 could offer improved tissue penetration and reduced immunogenicity for therapeutic applications.

• CRISPR screening combined with antibody detection: High-throughput screening to identify genes affecting FBN1 expression, secretion, or microfibril assembly, validated using FBN1 antibodies, could uncover new regulatory mechanisms.